MedTrace Logo

A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)

NCT04871997 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 373

Last updated 2022-10-21

No results posted yet for this study

Summary

A real-world study: Efficacy and safety of Anlotinib for advanced non-small cell lung cancer：This study aims to observe and explore the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer in the real world, and to summarize the treatment experience of a broad population.

Conditions

Sponsors & Collaborators

  • Qian Chu

    lead OTHER

Principal Investigators

  • Qian Chu · Tongji Hospital

  • Tienan Yi · Xiangyang Central Hospital

  • Youhong Dong · Xiangyang No.1 People's Hospital

  • Ruizhi Ran · The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture

  • Yang Fu · Xiangyang Hospital of Traditional Chinese Medicine

  • Guangqiao Qu · The Central Hospital of Xiao Gan

  • Jun Li · The Central Hospital of Xiao Gan

  • Yinping Li · The Central Hospital of Xiao Gan

  • Yanhua Xu · Jingzhou Central Hospital

  • Xinhua Xu · Yichang Central People's Hospital

  • Zhiguo Luo · Affiliated Taihe Hospital of Hubei University of Medicine

  • Fengjun Cao · Shiyan Renmin Hospital

  • Li Kuang · Dongfeng Hospital Affiliated to Hubei Medical College

  • Yifa Yin · Yichang Second People's Hospital

  • Guiming Chen · JingMen NO.2 People's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-12
Primary Completion
2022-07-16
Completion
2022-07-16

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04871997 on ClinicalTrials.gov